Crossmark

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib

Crossref DOI link: https://doi.org/10.1186/s13054-019-2385-x

Published Online: 2019-03-12

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nyga, Rémy

Simon, Laura

Chouaki, Taieb

Delette, Caroline

Bennis, Youssef

Joseph, Cedric

Marolleau, Jean-Pierre

Slama, Michel

Zogheib, Elie

Maizel, Julien http://orcid.org/0000-0001-5975-2635
License Information

Text and Data Mining valid from 2019-03-12
More Information

Article History

Received: 15 February 2019

Accepted: 6 March 2019

First Online: 12 March 2019

Ethics approval and consent to participate

: According to French legislation, the patient was informed and accepted in the department of hematology that data concerning his case might be subsequently used for scientific analyses and could be published with anonymized data.

: This paper concerns a retrospective case report of an individual patient. According to French legislation, the patient was informed and accepted in the department of hematology that data concerning his case might be subsequently used for scientific analyses, and could be published with anonymized data.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.